High Sensitive Troponin I and Extended Range C-Reactive Protein as Markers to Predict Cardiotoxicity in Locally Advanced Breast Cancer with Neoadjuvant CAF (Cyclophoshpamide, Adriamycin/Doxorubicin, 5Fluorouracil) Therapy

Yusfik Helmi Hidayat, Hantoro Ishardyanto, Leonita Anniwati

= http://dx.doi.org/10.20473/fmi.v56i2.21205
Abstract views = 381 times | downloads = 374 times

Abstract


The limitation of echocardiography to measure chemotherapy cardiotoxicity at left locally advanced breast cancer with large ulcer is still serious problem. HsTnI and erCRP are biomarkers to detect cardiotoxicity that are cheap, easy to examine and available at Dr.Soetomo Hospital Surabaya. This study was to compare HsTnI, erCRP and echocardiography as cardiotoxicity predictors in locally advanced breast cancer with neoadjuvant CAF therapy. This study used one group pretest and posttest design among 23 locally advanced breast cancer patients. All patients underwent echocardiography, HsTnI, and erCRP examinations before and after 3 times chemotherapy and compared. The average age was 49.78±8.7. Statistically significant decrease in LVEF was found after treatment (67.98%±4.06 and 64.07%±3.53, p=0.000). HsTnI was significantly increased after treatment (0.007 µg/mL±0.004 and 0.043 µg/mL±0.051 p=0.000). erCRP was significantly decreased after treatment (1.043mg/dL±0.913 and 0.573mg/dL±0.444 p=0.044). Decreased LVEF and increased HsTnI was compared by its cardiotoxic cut-off. HsTnI was significantly better and faster to detect cardiotoxicity (0.033±0.051 p=0.002). In conclusion, strong correlation is present in the detection of cardiotoxicity between HsTnI and LVEF. HsTnI is faster than echocardiography, and could be alternative diagnostic to detect early cardiotoxicity.

Keywords


Locally advanced breast cancer; doxorubicin; cardiotoxicity; LVEF; echocardiography; erCRP; HsTnI

Full Text:

PDF

References


Bovelli D, Plataniotis G, Roila F (2010). Cardiotoxicity of chemotherapeutic agents and radiotherapy-related heart disease: ESMO Clinical Practice Guidelines. Annals of Oncology 21, 277-282

Feola M, Garrone O, Occelli M, Francini A, Biggi A, Visconti G, et al (2011). Cardiotoxicity after anthracycline chemotherapy in breast carcinoma: effects on left ventricular ejection fraction, troponin I and brain natriuretic peptide. Int J Cardiol 148, 194-810. DOI: 1016/j.ijcard.2009.09.564

Garrone O, Crosetto N, Lo Nigro C, Catzeddu T, Vivenza D, Monteverde M, et al (2012). Prediction of anthracycline cardiotoxicity after chemotherapy by biomarkers kinetic analysis. Cardiovasc Toxicol 12, 135–4210. DOI: 1007/s12012-011-9149-4

Ky B (2014). Early increases in multiple biomarkers predict subsequent cardiotoxicity in patients with breast cancer treated with doxorubicin, taxanes and tratuzumab. Journal of the American College of Cardiology 63, 809-816

Limat S, Demesmay K, Voillat L, Bernard Y, Deconinck E, Brion A (2003). Early cardiotoxicity of the CHOP regimen in aggressive non-Hodgkin’s lymphoma. Annals of Oncology 14, 277-281

Lisi DD, Leggio G, Vitale G, Arrotti S, Iacona R, Inciardi RM, Nobile D, Bonura F, Novo G, Russo A, Novo S (2014). Chemotherapy cardiotoxicity: cardioprotective drugs and early identification of cardiac dysfunction. J Cardiovasc Med 16, 1-5

Onitilo AA, Engel JM, Liang H, et al (2012). High-sensitive C-reactive protein (Hs-CRP) as a biomarker for trastuzumab-induced cardiotoxicity in HER2-positive early-stage breast cancer: a pilot study. Breast Cancer Res Treat 134, 291-298

Pizzino F, Vizzari G, Bomzer CA, Qamar R, Carerj S, Zito C, Khandheria BK (2014). Diagnosis of chemotherapy-induced cardiotoxicity. Journal of Patient-Centered Research and Reviews 1, 120-127

Plana JC, Barac A, Ewer MS, Ky B, Scherrer-Crosbie M, Ganame J, Sebag IA, Agler DA, Badano LP, Banchs J, Cardinale D, Carver J, Cerqueira M, Decara JM, Edvardsen T, Flamm SD, Force T, Griffin BP, Jerusalem G, Liu JE, Magalhaes A, Marwick T, Sanchez LY, Sicari R, Villarraga HR, Lancellotti P (2014). Expert consensus for multimodality imaging evaluation of adult patients during and after cancer therapy: a report from the American Society of Echocardiography and the European Association of Cardiovascular Imaging. European Heart Journal - Cardiovascular Imaging 15, 1063-1093

Pusat Data dan Informasi Kementerian Kesehatan Indonesia. Data Epidemiologi Kanker Indonesia. 2015. Available at http://www.depkes.go.id/resources/ download/pusdatin/infodatin/infodatin-kanker.pdf. Accessed October 19, 2016

Reagan, Dolci A, Dominici R, Cardinale D, Sandri MT, Panteghini M (2008). Biochemical markers for prediction of chemotherapy-induced cardiotoxicity. Am J Clin Pathol 130, 688-695

Sawaya H (2012). American Heart Association: Assesment of echocardiography and viomarkers for the extended prediction in patients treated with antracyclines, taxanes, and trastuzumab. Boston, USA

Shaikh AS, Saleem AF, Mohsin SS, Alam MM, Ahmed MA (2013). Anthracycline-induced cardiotoxicity: prospective cohort study from Pakistan. BMJ Open 3, 1-6

Suyatno, Pasaribu ET (2010). Bedah onkologi diagnostik dan terapi 1st Ed. Jakarta, Sagung Seto

Torres VM, Simic VD (2012). Doxorubicin-induced oxidative injury of cardiomyocytes – Do we have right strategies for prevention? In: Fiuza M (ed). Cardiotoxicity of Oncologic Treatment. Croatia, InTech, p 277-282

Vetto JT, Luoh SH, Naik A (2009). Breast cancer in premenoupausal women Curr Probl Surg 46, 944-1004


Refbacks

  • There are currently no refbacks.


Copyright (c) 2020 Yusfik Helmi Hidayat, Hantoro Ishardyanto, Leonita Anniwati

Creative Commons License
This work is licensed under a Creative Commons Attribution-NonCommercial-ShareAlike 4.0 International License.

Indexed By

View My Stats

Creative Commons License

This work is licensed under a Creative Commons Attribution-NonCommercial-ShareAlike 4.0 International License.